Journal
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume 39, Issue 11, Pages 1784-1795Publisher
SPRINGER
DOI: 10.1007/s00259-012-2178-9
Keywords
Alzheimer's disease; Positron emission tomography; [F-18]Flutemetamol; [C-11]PIB
Funding
- Turku University Hospital [13464]
- Academy of Finland [17652]
- Sigrid Juselius Foundation
- EU 6th Framework Project ADIT [511977]
Ask authors/readers for more resources
The aim of this study was to investigate the potential of [F-18]flutemetamol as a preclinical PET tracer for imaging beta-amyloid (A beta) deposition by comparing its pharmacokinetics to those of [C-11]Pittsburgh compound B ([C-11]PIB) in wild-type Sprague Dawley rats and C57Bl/6N mice. In addition, binding of [F-18]flutemetamol to A beta deposits was studied in the Tg2576 transgenic mouse model of Alzheimer's disease. [F-18]Flutemetamol biodistribution was evaluated using ex vivo PET methods and in vivo PET imaging in wild-type rats and mice. Metabolism and binding of [C-11]PIB and [F-18]flutemetamol to plasma proteins were analysed using thin-layer chromatography and ultrafiltration methods, respectively. Radiation dose estimates were calculated from rat ex vivo biodistribution data. The binding of [F-18]flutemetamol to A beta deposits was also studied using ex vivo and in vitro autoradiography. The location of A beta deposits in the brain was determined with thioflavine S staining and immunohistochemistry. The pharmacokinetics of [F-18]flutemetamol resembled that of [C-11]PIB in rats and mice. In vivo studies showed that both tracers readily entered the brain, and were excreted via the hepatobiliary pathway in both rats and mice. The metabolism of [F-18]flutemetamol into radioactive metabolites was faster than that of [C-11]PIB. [F-18]Flutemetamol cleared more slowly from the brain than [C-11]PIB, particularly from white matter, in line with its higher lipophilicity. Effective dose estimates for [C-11]PIB and [F-18]flutemetamol were 2.28 and 6.65 mu Sv/MBq, respectively. Autoradiographs showed [F-18]flutemetamol binding to fibrillar A beta deposits in the brain of Tg2576 mice. Based on its pharmacokinetic profile, [F-18]flutemetamol showed potential as a PET tracer for preclinical imaging. It showed good brain uptake and was bound to A beta deposits in the brain of Tg2576 mice. However, its high lipophilicity might complicate the analysis of PET data, particularly in small-animal imaging.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available